Interviews

Ajai Chari, MD, addresses myeloma’s future: personalized care, shared decision-making, and why striving for a functional cure matters now.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Kerry Rogers, MD, discusses financial toxicity, equitable access to BTK inhibitors, and how frailty shapes CLL clinical trial design.

Erin L. Duffy, PhD, MPH, discusses her findings that nonprofit and system-affiliated hospitals have better multilingual access to financial aid documents.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.

The Rutgers School of Public Health dean reflects on activism, apathy, and the road to treatment.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

Seven oncology leaders reflect on lasting gains in patient care, cost awareness, and collaboration, and what was lost when CMS walked away.

Swarup Kumar, MD, discusses how myeloma programs can bridge gaps between academic innovation and community access for bispecific antibody therapy.

Sheng Fu, MD, explains why patients with overlapping cardiac, renal, and metabolic disease demand new care models.

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

Breast density raises cancer risk and masks tumors on mammography. Danielle Holt, MD, MSS, explains why density alone shouldn't trigger more imaging.

Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps when testing is negative for NSCLC.

Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD.

Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion.

Kerry Rogers, MD, outlines the cardiovascular risks of prolonged BTK inhibitor therapy in CLL and the major sequencing questions that remain unanswered.

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Fear of CPAP deters patients with OSA from seeking care. Experts call for early diagnosis with oral devices and warn payers about the cost of delays.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.

Alexander Spira, MD, PhD, FACP, FASCO, on why sarcoma diagnosis is often delayed and how community-academic collaboration speeds treatment.

The myeloma space has undergone tremendous transformation recently, says Prerna Mewawalla, MD, including CAR T-cell therapies and bispecific antibodies.